Strong Medicare Outlook Drives Wells Fargo’s Bullish Upgrade on Humana
Analyst highlights improving Medicare margins and star ratings for stronger 2028 earnings.
Already have an account? Sign in.
Analyst highlights improving Medicare margins and star ratings for stronger 2028 earnings.
The moves are aimed at supporting the company’s next phase of growth in precision peptide therapies.
H.C. Wainwright boosts Agenus’ price target to $30 from $23, reiterating a Buy rating.
RBC keeps Outperform at $242, Truist upgrades to Buy ($235 target).